Relapsed Or Refractory Multiple Myeloma

Also known as: Relapsed/ Refractory Multiple Myeloma / Relapsed and/or Relapsed-refractory Multiple Myeloma / Relapsed and/or Refractory Multiple Myeloma (RRMM) / Relapse or Refractory Multiple Myeloma / Relapsed, Refractory Multiple Myeloma / Relapsed/Refractory Multiple Myeloma(MM) / Relapsed/Refractory Multiple Myeloma / Relapse and/or Refractory Multiple Myeloma / Relapsed and/or Refractory Multiple Myeloma / Relapsed and Refractory Multiple Myeloma / Relapsed Refractory Multiple Myeloma / Relapsed, Refractory, Multiple Myeloma / Refractory or Relapsed Multiple Myeloma / Refractory, relapsed Multiple Myeloma / Relapsed/Refractory Multiple Myeloma (RRMM) / Relapsed-Refractory Multiple Myeloma / Plasma cell myeloma refractory

Drug	Drug Name	Drug Description
DB15719	Belantamab mafodotin	An anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
DB08889	Carfilzomib	A proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.
DB16627	Melphalan flufenamide	A melphalan prodrug used to treat relapsed or refractory multiple myeloma.

Drug	Drug Name	Target	Type
DB15719	Belantamab mafodotin	Solute carrier organic anion transporter family member 1B1	transporter
DB15719	Belantamab mafodotin	Solute carrier organic anion transporter family member 1B3	transporter
DB15719	Belantamab mafodotin	Multidrug resistance-associated protein 1	transporter
DB15719	Belantamab mafodotin	ATP-binding cassette sub-family C member 2	transporter
DB15719	Belantamab mafodotin	ATP-binding cassette sub-family C member 3	transporter
DB15719	Belantamab mafodotin	Bile salt export pump	transporter
DB15719	Belantamab mafodotin	ATP-dependent translocase ABCB1	transporter
DB15719	Belantamab mafodotin	Tumor necrosis factor receptor superfamily member 17	target
DB08889	Carfilzomib	ATP-dependent translocase ABCB1	transporter
DB08889	Carfilzomib	Proteasome subunit beta type-5	target
DB08889	Carfilzomib	Proteasome subunit beta type-9	target
DB08889	Carfilzomib	Proteasome subunit beta type-10	target
DB08889	Carfilzomib	Proteasome subunit beta type-8	target
DB08889	Carfilzomib	Proteasome subunit beta type-1	target
DB08889	Carfilzomib	Proteasome subunit beta type-2	target
DB16627	Melphalan flufenamide	Aminopeptidase N	enzyme
DB16627	Melphalan flufenamide	DNA	target

Drug	Drug Name	Phase	Status	Count
DB01234	Dexamethasone	Not Available	Approved for Marketing	1
DB16627	Melphalan flufenamide	Not Available	Approved for Marketing	1
DB16678	Talquetamab	Not Available	Approved for Marketing	1
DB00531	Cyclophosphamide	0	Unknown Status	1
DB01073	Fludarabine	0	Unknown Status	1
DB17357	AMG 424	1	Terminated	1
DB00188	Bortezomib	1	Unknown Status	1
DB16741	Bortezomib D-mannitol	1	Unknown Status	1
DB18374	Cevostamab	1	Recruiting	1
DB00531	Cyclophosphamide	1	Recruiting	1
DB09331	Daratumumab	1	Recruiting	2
DB01234	Dexamethasone	1	Completed	1
DB01234	Dexamethasone	1	Recruiting	2
DB01234	Dexamethasone	1	Terminated	1
DB01234	Dexamethasone	1	Unknown Status	1
DB15395	Elranatamab	1	Recruiting	1
DB15395	Elranatamab	1	Unknown Status	1
DB01073	Fludarabine	1	Recruiting	1
DB17251	ISB 1342	1	Completed	1
DB09570	Ixazomib	1	Completed	1
DB09570	Ixazomib	1	Terminated	1
DB00480	Lenalidomide	1	Recruiting	2
DB00480	Lenalidomide	1	Terminated	1
DB17430	MT-0169	1	Terminated	1
DB01204	Mitoxantrone	1	Unknown Status	1
DB12005	Nirogacestat	1	Recruiting	1
DB08910	Pomalidomide	1	Recruiting	1
DB11942	Selinexor	1	Completed	1
DB06273	Tocilizumab	1	Recruiting	1
DB08889	Carfilzomib	1 / 2	Recruiting	1
DB09331	Daratumumab	1 / 2	Recruiting	1
DB01234	Dexamethasone	1 / 2	Not Yet Recruiting	1
DB06317	Elotuzumab	1 / 2	Not Yet Recruiting	1
DB19015	Forimtamig	1 / 2	Recruiting	1
DB06186	Ipilimumab	1 / 2	Terminated	1
DB17280	OriCar-017	1 / 2	Recruiting	1
DB08910	Pomalidomide	1 / 2	Not Yet Recruiting	1
DB14851	Relatlimab	1 / 2	Not Yet Recruiting	1
DB19065	Renvistobart	1 / 2	Not Yet Recruiting	1
DB18374	Cevostamab	2	Recruiting	1
DB00531	Cyclophosphamide	2	Completed	1
DB09331	Daratumumab	2	Active Not Recruiting	1
DB09331	Daratumumab	2	Completed	1
DB01234	Dexamethasone	2	Active Not Recruiting	1
DB01234	Dexamethasone	2	Completed	2
DB01234	Dexamethasone	2	Terminated	1
DB06205	Hyaluronidase (human recombinant)	2	Active Not Recruiting	1
DB09570	Ixazomib	2	Active Not Recruiting	1
DB09570	Ixazomib	2	Completed	1
DB09570	Ixazomib	2	Terminated	1
DB08910	Pomalidomide	2	Active Not Recruiting	1
DB08910	Pomalidomide	2	Completed	1
DB08910	Pomalidomide	2	Terminated	1
DB00635	Prednisone	2	Completed	1
DB11942	Selinexor	2	Completed	1
DB00188	Bortezomib	3	Recruiting	1
DB16741	Bortezomib D-mannitol	3	Recruiting	1
DB08889	Carfilzomib	3	Completed	2
DB09331	Daratumumab	3	Terminated	1
DB01234	Dexamethasone	3	Completed	2
DB01234	Dexamethasone	3	Recruiting	2
DB01234	Dexamethasone	3	Terminated	1
DB06205	Hyaluronidase (human recombinant)	3	Terminated	1
DB00480	Lenalidomide	3	Completed	1
DB16627	Melphalan flufenamide	3	Terminated	1
DB17584	Mezigdomide	3	Recruiting	1
DB08910	Pomalidomide	3	Recruiting	2